Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Inhibitors of Viral Protein Synthesis

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

Insulin Formulations: Types and Delivery

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Inhibitors Of Virion Release

Inhibitors Of Virion Release

Viral replication and dissemination rely on efficient mechanisms for host cell entry, genome replication, assembly, and release. Influenza viruses, such as types A and B, are negative-sense single-stranded RNA viruses with a segmented genome, that depend on two critical surface glycoproteins to carry out these processes: hemagglutinin (HA) and neuraminidase (NA). HA initiates infection by binding to sialic acid residues on the surface of host epithelial cells, facilitating receptor-mediated...

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

Modified-Release Drug Delivery Systems: Rate-Programmed II

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Correction to: Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA.

Drugs & therapy perspectives : for rational drug selection and use·2019

Same author

Risankizumab: First Global Approval.

Drugs·2019

Same author

Ravulizumab: First Global Approval.

Drugs·2019

Same author

<i>Ginkgo biloba</i> extract EGb 761<sup>®</sup> in the symptomatic treatment of mild-to-moderate dementia: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2018

Same author

Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA.

Drugs & therapy perspectives : for rational drug selection and use·2018

Same author

Nanosomal Docetaxel Lipid Suspension: A Guide to Its Use in Cancer.

Clinical drug investigation·2017

Search research articles

Related Experiment Video

Updated: Jul 11, 2026

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Subcutaneous interferon-beta-1a : new formulation.

Kate McKeage¹, Antona J Wagstaff

¹Wolters Kluwer Health, Adis, Auckland, New Zealand. demail@adis.co.nz

|September 14, 2007

Summary

This summary is machine-generated.

A new subcutaneous interferon-beta-1a formulation for multiple sclerosis (MS) shows promise, with fewer patients developing neutralizing antibodies (NAbs) and similar relapse-free rates compared to the current version.

More Related Videos

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Related Experiment Videos

Last Updated: Jul 11, 2026

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Area of Science:

Neuroimmunology
Pharmacology
Clinical Therapeutics

Background:

Multiple sclerosis (MS) management often involves interferon-beta therapies.
Current formulations can elicit immunogenicity and injection site reactions.
A novel subcutaneous interferon-beta-1a formulation was developed serum-free to enhance tolerability and immunogenicity.

Purpose of the Study:

To evaluate the immunogenicity and clinical efficacy of a new subcutaneous interferon-beta-1a formulation in relapsing MS patients.
To compare the incidence of neutralizing antibodies (NAbs) with a historical control group.

Main Methods:

An interim analysis of a single-arm, phase IIIb trial involving MS patients receiving subcutaneous interferon-beta-1a 44 mcg three times weekly.
Comparison of NAb development and relapse rates against historical data from the EVIDENCE trial.
Pharmacokinetic assessment in a phase I study in healthy volunteers.

Main Results:

At 48 weeks, 13.9% of patients on the new formulation developed NAbs, versus 24.4% in the historical EVIDENCE trial.
Approximately two-thirds of patients remained relapse-free, comparable to historical data.
The new formulation showed similar pharmacokinetics to the current one.
A potential trend towards fewer injection-site reactions but more influenza-like symptoms was observed.

Conclusions:

The new serum-free subcutaneous interferon-beta-1a formulation demonstrates potentially improved immunogenicity with comparable efficacy to the current formulation.
While generally well-tolerated with mild to moderate adverse events, further monitoring for injection site reactions and influenza-like symptoms is warranted.